Combination therapy for advanced myeloproliferative neoplasms
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new combination of three drugs (pacritinib, venetoclax, and azacitidine) for people whose myeloproliferative neoplasm (MPN) has progressed to a more aggressive phase. The goal is to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with essential thrombocythemia, polycythemia vera, or primary myelofibrosis, and your disease has progressed to an accelerated or blast phase (higher number of blast cells in blood or bone marrow).
- You have not received prior treatment for blast phase disease, except for hydroxyurea or a JAK inhibitor (like ruxolitinib).
- Your white blood cell count is below 25,000 per microliter before starting treatment (or can be lowered with hydroxyurea or leukapheresis).
- Your liver and kidney function are within acceptable limits, as determined by blood tests.
- You have not previously taken venetoclax or similar drugs (BCL-2 inhibitors).
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use highly effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether venetoclax together with azacitidine can shrink and control advanced blood cancers caused by myeloproliferative neoplasms (MPN) that do not have the BCR-ABL gene. It may help people whose disease has moved into an accelerated or blast phase when standard options haven’t yet included blast-reducing treatment.
This trial tests adding pacritinib to standard hypomethylating agents (azacitidine or decitabine) before a stem cell transplant for people with myeloproliferative neoplasms (MPN) that have progressed to a more advanced phase.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
This trial tests a drug called pacritinib for people with CMML. It's for those who haven't had JAK inhibitor therapy before and may have had only one cycle of other treatments.
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.